Prolonged toxicity in a 2-year-old after accidental ingestion of aripiprazole

Pediatric Emergency Care

Volumn 25, Issue 2, 2009, Pages 105-106

  Melhem, Samer ^a,b   Katz, Kenneth ^a,b   Jameson, Angus ^a   Shellenbarger, David ^a   Akhtar, Jawaid ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Aripiprazole; Toxicity

Indexed keywords

ARIPIPRAZOLE; CAFFEINE; LIDOCAINE; NICOTINE;

ARTICLE; ATAXIA; BLOOD CELL COUNT; BRAIN TOMOGRAPHY; CASE REPORT; CHILD; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG URINE LEVEL; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEAD POSITION; HUMAN; IRRITABILITY; LETHARGY; LUMBAR PUNCTURE; PATIENT MONITORING; PHYSICAL EXAMINATION; PRESCHOOL CHILD; TACHYCARDIA; TREMOR; VITAL SIGN;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; INFANT; PIPERAZINES; POISONING; QUINOLONES;

EID: 66249147572     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/PEC.0b013e318196faaf     Document Type: Article

References (14)

1. TM (aripiprazole) tablets [package insert]. New York: Bristol Myers Squibb Co; 2007.
2. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26(5):649-666.
3. Lofton AL, Klein-Schwartz W. Atypical experience: a case series of pediatric aripiprazole exposures. Clin Toxicol (Phila). 2005;43(3): 151-153.
4. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short term, placebo controlled trials. Schizophr Res. 2003;61(2-3):123-136.
5. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400-1411.
6. Sajatovic M. Treatment for mood and anxiety disorders: quetiapine and aripiprazole. Curr Psychiatry Rep. 2003;5:320-326.
7. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers in the treatment of schizophrenia. Curr Drug Targets CNS Neurol Disord. 2002;1(2):141-147.
8. Findling RL, Blumer J, Kauffman R, et al. Pharmacokinetic and pharmacodynamic effects of aripiprazole in conduct disorder. Poster presented at 50th Anniversary Meeting of the American Academy of Child and Adolescent Psychiatry; October 14-19, 2003; Miami Beach, FL.
9. Davenport JD, McCarthy MW, Buck ML. Excessive somnolence from aripiprazole in a child. Pharmacotherapy. 2004;24(4):522-525.
10. Singh MK, Delbello MP, Adler CM. Acute dystonia associated with aripiprazole in a child. J Am Acad Child Adolesc Psychiatry. 2007; 46(3):306-307.
11. Seifert SA, Schwartz MD, Thomas JD. Aripiprazole (Abilify) overdose in a child. Clin Toxicol (Phila). 2005;43(3):193-195.
12. Schonberger RB, Douglas L, Baum CR. Severe extrapyramidal symptoms in a 3-year-old boy after accidental ingestion of the new antipsychotic drug aripiprazole. Pediatrics. 2004;114(6):1743.
13. Huang HC, Liu CH, Tan TH, et al. Detection and quantification of aripiprazole and its metabolite, dehydroaripiprazole, by gas chromatography-mass spectrometry in blood samples of psychiatric patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 856(1-2):57-61.
14. de Leon J, et al. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47:75-85.